Myeloma's Hidden Allies: How Bone Marrow Stroma and Vessels Fuel Cancer's Spread
"Uncover the crucial role of the bone marrow microenvironment in myeloma's progression and discover potential new targets for treatment."
Bone metastasis, the spread of cancer to the bones, is a complex process involving various cell populations and regulatory proteins. While cancers like breast, prostate, lung, and thyroid often spread to the bone, multiple myeloma (MM) has a unique connection to the bone marrow. This process involves circulating tumor cells (CTCs) finding specialized bone marrow "niches" to settle and grow.
After arriving in the bone marrow, these tumor cells interact with the local environment, influencing their survival, dormancy, or proliferation. The tumor cells adapt to evade the immune system, either remaining dormant or multiplying to form bone metastases, ultimately disrupting normal bone physiology.
The bone marrow's rich blood supply and adhesive molecules on tumor cells facilitate this process. Factors within the bone marrow, such as acidity and low oxygen levels, can also promote tumor growth and drug resistance. Additionally, chemokines like osteopontin act as chemoattractants for cancer cells.
Why the Marrow Matters
Multiple myeloma develops within the bone marrow, where interactions among malignant plasma cells, surrounding stromal cells, and blood vessels can influence disease behavior. These interactions may help explain why the cancer can persist, damage bone, and sometimes spread beyond the marrow. Their importance is an active area of research rather than a settled explanation for every patient's course.
Limits of Conventional Care
Standard myeloma care generally combines diagnostic testing with systemic treatment and monitoring for complications such as bone damage. These approaches can control disease, but they do not necessarily eliminate every malignant cell or fully disrupt the supportive marrow environment. Because myeloma biology varies among patients, treatment effectiveness and durability can differ.
From First Case to Evolutionary Models
Historical reviews trace multiple myeloma from the description of the first case in 1844 through the development of drug therapy, stem-cell transplantation, and newer agents. More recent work has examined the evolutionary history of multiple myeloma and its precursors, focusing on the chronological order in which disease drivers arise. This evolutionary perspective may help determine when and how patients should be treated, while clinical discussions increasingly consider screening and earlier detection. By diagnosis, more than 80% of patients are reported to have symptoms of bone damage, including pain or fractures.
The Bone Marrow Niche: A Supportive Environment for Myeloma
The bone marrow (BM) niche plays a crucial role in supporting myeloma cell survival and proliferation. The BM comprises hematopoietic cells (myeloid cells, T lymphocytes, B lymphocytes, natural killer (NK) cells, monocytes, macrophages, dendritic cells, osteoclasts, erythrocytes, megakaryocytes, and platelets) and non-hematopoietic cells (fibroblasts, adipocytes, osteoblasts, endothelial cells, and blood vessels). Each BM cellular compartment provides the structural and physiological support for hematopoietic cells and may also modulate MM cell homing and progression.
- Cell Adhesion: Myeloma cells strongly adhere to BMSCs, promoting myeloma cell growth, proliferation, and drug resistance. Molecules like CD44, VLA-4, VLA5, LFA1, NCAM, ICAM1, syndecan-1, CD40/CD40L, and beta-1 and beta-2 integrin mediate this adhesion.
- Cytokine Support: Cytokines like IL-6, secreted by BMSCs, are key growth and survival factors. IL-6 activates signaling cascades and anti-apoptotic proteins, conferring drug resistance.
- Angiogenic Molecules: BMSCs from MM patients express pro-angiogenic molecules like VEGF, Ang-1, bFGF, PDGF, HGF, TGF-x, and IL-1, which promote blood vessel formation.
- GDF15 Influence: Growth differentiation factor 15 (GDF15), aberrantly expressed by MM-derived BMSCs, increases the survival of stroma-dependent myeloma cells and enhances their tumor-initiating potential.
- SDF-1/CXCR4 Axis: The stromal cell-derived factor 1 (SDF-1)/CXCR4 axis is critical for BMSC-myeloma interaction, facilitating homing and engraftment of myeloma cells in the BM. Targeting SDF-1 can prevent disease progression and enhance sensitivity to anti-MM agents.
- Exosome Communication: BMSC-derived exosomes, containing proteins and RNA, are transferred to myeloma cells, affecting their growth and drug resistance. These exosomes influence survival pathways and have differing microRNA content compared to normal BMSC-derived exosomes.
An Active Research Field
Current reviews continue to examine how myeloma cells interact with the bone marrow environment, including stromal and vascular components. This work is intended to clarify why disease can persist, relapse, or spread outside the marrow. However, research findings do not yet support a single universally effective strategy for targeting every component of this ecosystem.
Why Control Is Not Cure
The marrow microenvironment is unlikely to be the sole explanation for treatment failure, because myeloma is biologically diverse and patients can follow different disease trajectories. Approaches aimed at one supportive pathway may therefore have limited effects when other cellular or molecular interactions remain active. Evidence about these mechanisms is still developing, so proposed explanations should not be treated as definitive for all cases.
Myeloma Versus Metastasis
Multiple myeloma and metastatic cancer are both common malignant bone-marrow lesions, and similar imaging findings can make them difficult to distinguish. One study evaluated whether adding diffusion-weighted imaging to standard MRI could improve differentiation, while another investigated machine learning based on conventional MRI sequences for distinguishing myeloma from tumor metastases in lumbar vertebrae. In practice, clinicians may combine blood tests, scans, and biopsies when evaluating the difference.
Future Directions: Targeting the Bone Marrow Niche
Metastasis remains a critical, unresolved issue for cancer patients. Given the heterogeneity of tumors, especially in myeloma, and their supportive microenvironment, targeting both the tumor clone and the microenvironment is essential to improve outcomes.
A Connected Disease Ecosystem
The available perspective supports viewing myeloma as more than a collection of malignant plasma cells. The surrounding marrow environment may contribute to cancer persistence, bone injury, and dissemination, but its precise influence varies with disease biology. A balanced interpretation therefore treats stromal and vascular interactions as important contributors rather than complete explanations.
Earlier Detection and Durable Control
A 2026 update describes multiple myeloma diagnosis as requiring at least 10% clonal bone-marrow plasma cells or a biopsy-proven plasmacytoma, together with one or more myeloma-defining events such as CRAB features, bone-marrow clonal plasmacytosis of at least 60%, or a qualifying free-light-chain finding. The same source and a 2026 New England Journal of Medicine review highlight the importance of distinguishing active disease from smoldering myeloma, which may involve at least 10% marrow plasma cells or a monoclonal component of at least 3 g per deciliter. Other 2026 reports describe major therapeutic progress, including claims that some patients are being cured and that nearly two-thirds of newly diagnosed patients live at least five years, although these reported outcomes should be interpreted in the context of their differing sources and claims.
Heterogeneity and Escape
Multiple myeloma remains difficult to manage because of its heterogeneity and tendency to relapse and progress. Recent expert discussions identify continuing gaps and controversies in management, while research on the bone-marrow barrier emphasizes its role in plasma-cell homing and disease progression. Advanced disease can also form lesions that destroy bone and spread to other parts of the body.
When Diagnoses Overlap
A 2023 case report described the coexistence of multiple myeloma and bone-metastatic clear cell renal cell carcinoma in the spine. Pathology and immunohistochemistry established both diagnoses, after which clinicians used immunotherapy and systemic chemotherapy and performed vertebral decompression after correcting anemia. The case illustrates how overlapping marrow and bone disease can complicate diagnosis and require individualized treatment.
Future research should focus on developing therapeutic strategies to target the stroma and vasculature in myeloma and other bone metastatic diseases. Understanding the mechanisms of anti-cancer therapies, such as the anti-angiogenic effects of bisphosphonates, is also crucial.
Ongoing clinical trials are evaluating CXCR4-targeting agents, reflecting the importance of this pathway in myeloma dissemination. Targeting the BM microenvironment and its niches represents a promising area for future drug development.